Recent Investment Analysts’ Ratings Updates for Insmed (INSM)

A number of research firms have changed their ratings and price targets for Insmed (NASDAQ: INSM):

• 7/28/2026 – Insmed had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $235.00 price target on the stock.
• 7/20/2026 – Insmed is now covered by BMO Capital Markets. They set an “outperform” rating and a $192.00 price target on the stock.
• 7/20/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright. They now have a $220.00 price target on the stock.
• 7/20/2026 – Insmed was upgraded by BMO Capital Markets to “strong-buy”.
• 7/17/2026 – Insmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Insmed had its price target raised by Wells Fargo & Company from $160.00 to $161.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Insmed had its “buy” rating reaffirmed by Guggenheim. They now have a $207.00 price target on the stock.
• 6/16/2026 – Insmed was given a new $192.00 price target by Mizuho.
• 6/10/2026 – Insmed had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/8/2026 – Insmed had its “buy” rating reaffirmed by Roth Capital.
• 6/8/2026 – Insmed had its price target lowered by JPMorgan Chase & Co. from $180.00 to $179.00. They now have an “overweight” rating on the stock.
• 6/5/2026 – Insmed had its price target lowered by Royal Bank Of Canada from $205.00 to $195.00. They now have an “outperform” rating on the stock.

Insiders Place Their Bets

In related news, insider Michael Alexander Smith sold 6,149 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $108.47, for a total value of $666,982.03. Following the transaction, the insider owned 41,613 shares in the company, valued at approximately $4,513,762.11. This represents a 12.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 2,370 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $242,379.90. Following the completion of the transaction, the chief operating officer directly owned 98,603 shares in the company, valued at approximately $10,084,128.81. This represents a 2.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 54,590 shares of company stock valued at $5,793,738 over the last 90 days. 2.10% of the stock is owned by insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.